Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0
Supplementary Table S3-4 caption from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0
Supplementary Table S4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0
Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Rebecca Aft et al.|Unknown|2023Cited by 0
Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0